Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. Diabetes mellitus (DM) is both a risk factor for and a sequela of PDAC. Metformin is a commonly prescribed biguanide oral hypoglycemic used for the treatment of type II DM. We investigated whether metformin use before PDAC diagnosis affected survival of patients with DM, controlling confounders such as diabetic severity.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. Th e 5-year survival rate for PDAC is 6.5%, increased only slightly from 2.4% four decades ago ( 1 ) . In 2015, 48,960 cases were diagnosed in the United States, with 40,560 deaths ( 2 ) . Th is slow progress has yielded increased interest over the last several years to explore the anti-neoplastic eff ects of already-approved medications as potential adjunctive therapies for pancreatic cancer.
Th ese medications have established safety profi les, making them particularly appealing from a drug repurposing development perspective. Metformin is a commonly prescribed biguanide oral hypoglycemic used for the treatment of type II diabetes mellitus (DM). It works mechanistically by increasing insulin sensitivity and decreasing hepatic glucose production.
Large studies have confi rmed that patients with DM are at an increased risk of developing several cancers including pancreatic,
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Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis colon, liver, breast, and lung (3) (4) (5) (6) (7) (8) (9) . Furthermore, diabetic patients with cancer tend to have worse survival, and metformin has been shown to both decrease the risk of cancer and improve survival among diabetics with cancer ( 3, 4, (10) (11) (12) .
Th e aim of our study was to use a nationally representative population-based cancer database to investigate whether metformin use before PDAC diagnosis aff ected survival of patients with known DM, controlling for diabetic severity and concurrent use of other diabetic medications.
METHODS
Th e analysis was performed using the Surveillance, Epidemiology, and End Results registry (SEER) linked to Medicare claims ( 13 ) . Included patients were 65 years or older and diagnosed with histologically confi rmed PDAC between 2007 and 2011 ( Figure 1 ). Th is date range was chosen as Medicare Part D data, which provide information on medication use, are only available from 2007. Patients over age 65 were included because this is the age of enrollment in Medicare coverage in the United States. We excluded patients with more than one primary cancer to eliminate the eff ect of synchronous or metachronous lesions on prognosis. Individuals without Part B Medicare coverage, which covers outpatient visits, Part D Medicare coverage, or those in HMO (health-care maintenance organizations), were further excluded for incomplete claims ( 14 ) . Adenocarcinoma was selected for using the International Classifi cation of Diseases for Oncology, Second Edition (ICD-O-2, 1992) histology codes 8000, 8010, 8140, 8500, 8550, and 8560.
Sociodemographic characteristics and comorbidities
Sociodemographic information was obtained from both the SEER and Medicare-linked databases. We controlled for comorbidities such as cardiovascular disease and chronic kidney disease (CKD), using the Deyo adaption of the Charlson comorbidity index (15) (16) (17) . Both inpatient and outpatient hospital claims (Medicare Provider Analysis and Review, Outpatient Standard Analytical File) as well as diagnoses on claims submitted by individual physicians (Carrier fi le) were included to increase the possibility of identifying more comorbid conditions ( 14, 17 ) .
Diabetes and diabetic regimen
Diabetic patients were identifi ed according to validated algorithm for Medicare claims-based data requiring the presence of International Classifi cation of Diseases, 9 th Revision (ICD-9), code "250.xx" ( 18, 19 ) . Inclusion in our DM cohort required either one hospital claim or two outpatient claims more than 1 year but less than 2 years before PDAC diagnosis. We excluded patients diagnosed with DM in the year before PDAC diagnosis to minimize the eff ect of pancreaticogenic (type 3c) diabetes (reverse causation). Use of DM medications was extracted from Medicare Part D claims. Patients were considered to have used a specifi c DM medication if the pharmacy claim was submitted within 6 months before cancer diagnosis. Patients without any DM medications during this period were excluded. Specifi c categories of anti-hyperglycemics studied were metformin, insulin, sulfonyl urea, thiazolidinediones (TZDs), dipeptidyl peptidase-4 inhibitors (DPP4-i), meglitinides, and alpha glucosidase inhibitors. Patients on combination medications were considered users of both drugs. DM severity, as manifested by end-organ damage and diabetes-related complications, was controlled for using the diabetic comorbidity severity index (DCSI). Th e DCSI is a validated, claims-based severity score ( 20, 21 ) . As it is disease specifi c to DM, it may predict additional or disparate health outcomes that may not be captured through generic risk adjustment tools such as the Charlson score ( 20, 21 ) .
Tumor characteristics and treatment
Tumor characteristics such as histology and stage, as well as treatment characteristics such as cancer-directed surgery and radiation therapy, were ascertained from the general SEER database. Chemotherapy administration was identifi ed from the Medicare claims (Medicare Provider Analysis and Review, Carrier, Outpatient Standard Analytical File) using the International Classifi cation of Diseases, 9 th Revision, Clinical Modifi cation (ICD-9-CM) procedure code 99.23 and the Healthcare Common Procedure Coding System codes (HCPCS) Q0083, Q0084, Q0085, J7150, J3253, J3259, and J9000-J9999 aft er the cancer diagnosis ( 22, 23 ) .
Study outcome
Th e primary outcome of the study was overall survival. Survival times were calculated as the period from the date of diagnosis of PDAC to the date of death. Subjects alive on 15 December 2011 were censored.
Statistical analysis
Demographic characteristics were compared between diabetics on metformin and those on other diabetic medications using the chi-squared test for categorical variables and Student's T -test for continuous variables.
Propensity score methods were used to control for potential allocation bias, as DCSI and comorbidity status (e.g., CKD) may infl uence a physician's decision to prescribe metformin. Th e propensity score thus represents the likelihood that a patient will receive metformin based on his/her known characteristics ( 24 ) . We used a logistic regression model to calculate propensity scores based on each patient's sociodemographic characteristics (sex, marital status, income quartile), comorbidity status (Charlson score, CKD), DCSI, and DM medications (insulin, sulfonylurea, TZD, meglitinide, DPP4-i, alpha-glucosidase inhibitor).
Survival analysis was performed using Kaplan-Meier methods to test survival diff erences between DM patients on metformin compared with DM patients on medications other than metformin, as well as for patients on each of the other DM medications (insulin, sulfonylurea, TZD, meglitinide, DPP4-i, alpha-glucosidase inhibitor) compared with patients not on those medications. Cox proportional-hazards modeling was then employed using inverse propensity weighting to adjust for confounders such as propensity score, stage, and treatment characteristics (cancer-directed surgery, radiation therapy, and chemotherapy). Finally, we conducted stratifi ed analysis by comorbidity status (Charlson score, CKD), diabetic severity (DCSI score), insulin use, sulfonylurea use, and length of time on metformin. All analyses were performed using SAS 9.3 (SAS, Cary, NC).
RESULTS
We identifi ed 1,916 subjects with pancreatic adenocarcinoma and a diagnosis of DM at least 1 year before cancer diagnosis ( Table 1 ). Of these, 1,098 (57%) patients were treated with metformin in the 6 months before cancer diagnosis. Th e remaining 818 (43%) patients were treated with diabetic medications other than metformin.
Aft er propensity weighting, a statistical method described above that represents the likelihood that a patient will receive metformin, there were no diff erences with regard to demographics characteristics or medication usage between the two groups ( Tables 1  and 2 ). Specifi cally, patients treated with metformin were equally matched in terms of comorbidities and diabetic severity compared with patients not on metformin ( P =0.96 and P =0.94, respectively) ( Table 1 ) . Similarly, patients on metformin were equally likely to be taking insulin or a sulfonylurea compared with patients not on metformin ( P =0.62 and P =0.98, respectively) ( Table 2 ). With regard to treatment, patients on metformin received more cancerdirected treatment (surgery, radiation, and chemotherapy) than patients on other medications ( P <0.01) ( Table 2 ) ; however, these diff erences were controlled for in the multivariate survival analysis model.
On Kaplan-Meier analysis, patients on metformin had improved survival compared with DM patients on medications other than metformin (overall survival 5.5 vs. 4.2 months, log-rank P <0.01) ( Figure 2 ). When stratifi ed by stage, this result persisted for all stages, except Stage 1 PDAC ( Table 3 ) . Furthermore, aft er adjusting for confounders including stage and treatment, as well as medication use, diabetic severity, and comorbidities by inversely weighting our Cox-Proportional Hazard model by the propensity score, these survival diff erences remained. Patients on metformin had a 12% decreased risk of mortality compared with patients on medications other than metformin (hazard ratio (HR) 0.88, 95% confi dence interval (CI) 0.81-0.96, P <0.01) ( Table 4 ) .
On univariate Kaplan-Meier analysis, patients on insulin had worse survival than patients not on insulin (4.3 vs. 5.5 months, P <0.01). No other diabetic medications were associated with survival diff erences ( Table 5 ). Adjusted analyses were not performed for these medications.
Sensitivity analyses were performed, in addition to the propensity analysis and multivariate survival analysis, in order to confi rm that the survival advantage seen with metformin was not due to inherent diff erences between the two study groups. Sensitivity analyses stratifi ed by the Charlson score, the presence of CKD, CKD, chronic kidney disease. a Refl ects differences between groups after adjusting for propensity score for metformin.
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and those who were on metformin for >2 years before diagnosis had improved survival compared with those patients not on metformin. Th e HR for death from PDAC among those taking metformin for >2 years was 0.88 (95% CI 0.79-0.98, P =0.02) compared with those not on metformin. Th e HR for those on metformin <6 months was 0.87 (95% CI 0.75-1.01, P =0.07) compared with those not on metformin.
DISCUSSION
DM is a known-risk factor for PDAC, and recent pooled casecontrol studies suggest that metformin use at any time may reduce the incidence of PDAC ( 3, 25, 26 ) . Nevertheless, little is known regarding the prognosis of diabetic patients taking metformin at the time of cancer diagnosis compared with those on other medications. We used a population-based data set to show that, among PDAC patients with pre-existing DM, those taking metformin at the time of cancer diagnosis have improved survival compared with patients taking diabetic medications other than metformin, controlling for comorbidities, diabetic severity, sociodemographic, and treatment characteristics. Prior studies examining the eff ects of metformin among diabetic patients with PDAC are confl icting. With regard to incidence, case-control and cohort studies have suggested that metformin use at any time reduces incidence of PDAC among diabetics, whereas insulin and insulin secretagogues increase the risk ( 3, (25) (26) (27) . However, a recent meta-analysis of 11 studies and 1,770 cases of PDAC in 730,664 patients with DM found no signifi cant association between metformin, insulin, or TZDs and the risk of developing PDAC ( 28 ) . With regard to survival of diabetics with PDAC, two studies on metformin use have been published. A single-center study of 302 patients with PDAC and DM found a 36% lower risk of death among patients with non-metastatic disease who received metformin; however, this study was not able to control for diabetic severity ( 29 ) . Furthermore, recall bias may have been a signifi cant issue in this study, as detailed medical information was obtained via personal interview for 76% of patients. A UK-based population cohort of 516 patients with stage IV PDAC and DM found no diff erence in survival among patients taking metformin, but this study did not control for race or concurrent use of other diabetic medications such as insulin ( 30 ) . Our study is the fi rst US-based population study to examine the eff ects of metformin on DM patients while controlling for diabetic severity and concurrent use of other DM medications. Our data demonstrate a protective eff ect of metformin for both metastatic and non-metastatic disease.
From a mechanistic point of view, metformin inhibits PDAC cell growth by lowering insulin and IGF-1 levels ( 31,32 ). Th ese hormones stimulate neoplasia via their interaction with G-protein-coupled receptors that promote mitogenic signaling. Metformin also has a direct inhibitory eff ect on PDAC cells by activating AMP-activated protein kinase, which in turn inactivates the mammalian target of the rapamycin pathway-a regulatory pathway that promotes cell proliferation (33) (34) (35) (36) . Our data support this mechanism as diabetics on insulin in our cohort had worse survival, and even among patients on insulin, metformin had a protective eff ect ( Figure 3e ). Furthermore, no other diabetic medications improved survival, suggesting that this protective eff ect is specifi c to metformin.
Duration of metformin use may impact survival. To address this concern, we performed a sensitivity analysis comparing patients who had received metformin for >2 years before PDAC diagnosis with patients who received their fi rst metformin prescription <6 months before diagnosis. Although the HR was signifi cant only for those on metformin >2 years, the point estimate for the HR is similar (0.88 for those on metformin >2 years vs. 0.87 for those on metformin <6 months). Th is diff erence is likely due to diminished power to detect a diff erence in survival for those on metformin <6 months, as only 204 subjects met this criterion. In contrast, 459 subjects were on metformin for >2 years and 818 subjects were not on metformin. Part D (prescription) coverage for Medicare became available in the SEER-Medicare database in 2007, resulting in a limited sample size of diabetic PDAC subjects with long-term prescription information.
Increasing evidence suggests that there may be a bi-directional relationship between diabetes and PDAC. In addition to being a risk factor for PDAC, diabetes can also occur as a consequence of PDAC-either from insulin resistance and islet cell dysfunction, chronic obstruction of the pancreatic duct with upstream glandular atrophy and loss of islet cells, or simply loss of islet cells post resection ( 6, 37, 38 ) . To mitigate the eff ect of type 3c DM (reverse causation), we included only subjects with a diagnosis of DM at least 1 year before PDAC diagnosis.
If PDAC cases were ascertained because of a new diagnosis of DM, then this may create lead-time bias and impact survival in our study. Exclusion of subjects diagnosed with DM <1 year before PDAC diagnosis also serves to minimize the impact of lead-time bias, which we expect to be minimal for cases of DM >1 year before PDAC diagnosis given the rapidly progressive nature of PDAC.
Our study has several strengths. Notably, this is the only USbased population study to examine the eff ect of metformin use at diagnosis on survival among patients with DM and PDAC. Our sample size is signifi cantly larger than previously-published studies, and we use validated methodology to extract claims from a widelyutilized national epidemiological database. However, several limitations inherent with the use of claims data must be addressed. First, our study was retrospective and therefore not randomized. To address this, we used propensity scoring to estimate the probability that patients would receive metformin based on his/her baseline characteristics. Propensity scores control for allocation bias that may occur as a result of diff erences in diabetic severity, comorbidities, or other factors that may infl uence a prescriber's decision to use metformin in a particular patient ( 24, 39 ) . Aft er applying this method, no signifi cant diff erences remained between metformin users vs. non-users ( Tables 1 and 2 ). We weighted our Cox models by the inverse of the propensity score and also controlled for additional confounders such as stage, and receipt of various treatments such as surgery, chemotherapy, and radiation to ensure that the two groups were equally matched. Second, DM patients not on metformin at the time of PDAC diagnosis appeared to be sicker, as suggested by higher Charlson and DCSI scores, and less likely to be on insulin ( only performed a propensity analysis as above but also performed stratifi ed analyses by comorbidity status, diabetic severity, and insulin use to investigate any confounding that may not have been controlled for in our multivariate survival analysis ( Figure 3 ) . We found that, regardless of Charlson, DCSI score, CKD, or insulin use, diabetic PDAC patients on metformin had improved survival compared with patients on medications other than metformin. A third limitation with any claims database is the concern for misclassifi cation bias. SEER-Medicare relies on physician coding and data entry, which may at times be driven by monetary concerns rather than medical indication. However, any misclassifi cation is likely to be non-diff erential with respect to the outcome, and its eff ect is likely to underestimate diff erences between groups. Fourth, our study uses pharmacy claims as a proxy for diabetic medication use and therefore assumes patient adherence. Nevertheless, the lack of adherence would have biased our results toward the null and prescription claims data have been shown to be a reliable estimate of medication adherence in older people ( 40 ) . Fift h, we were unable to control for certain established survival determinants of PDAC, such as smoking, ASA score, liver specifi c metastases, CA 19-9 levels, CEA levels, or daily pain score, as these variables are not available in the SEER-Medicare database (41) (42) (43) . Nevertheless, we were able to control for several other established prognostic factors such as age, race, sex, American Joint Committee on Cancer stage, diabetic severity, comorbidity, and treatment received (chemo, radiation, surgery) in our propensity-weighted multivariate survival analysis ( Table 4 ). Finally, we were unable to assess the survival benefi t of metformin by dose response in this study. Future studies that consider metformin dose would provide stronger evidence of a survival benefi t.
In conclusion, these data suggest that diabetic patients receiving metformin at the time of PDAC diagnosis have improved survival compared with patients on other medications. Th is eff ect of metformin in PDAC persists for both non-metastatic and metastatic disease, is consistent with that reported for other cancers, and accounts for comorbidity status, diabetic severity, treatment, and concurrent use of other diabetic agents such as insulin. Further prospective studies in conjunction with chemotherapy are needed to confi rm these fi ndings.
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